• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that an investigator-sponsored trial of its monocolonal antibody bavituximab for patients with Stage II or Stage III rectal adenocarcinoma has been initiated. The open-label Phase I trial will enroll up to 18 patients to receive the antibody in combination with capcitabine and radiation for eight weeks.